Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Schildhaus, Hans-Ulrich, Schultheis, Anne M., Rüschoff, Josef, Binot, Elke, Merkelbach-Bruse, Sabine, Fassunke, Jana, Schulte, Wolfgang, Ko, Yon-Dschun, Schlesinger, Andreas, Bos, Marc, Gardizi, Masyar, Engel-Riedel, Walburga, Brockmann, Michael, Serke, Monika, Gerigk, Ulrich, Hekmat, Khosro, Frank, Konrad F., Reiser, Marcel, Schulz, Holger, Krüger, Stefan, Stoelben, Erich, Zander, Thomas, Wolf, Jürgen, Buettner, Reinhard · 2015 · Clinical Cancer Research

Abstract

Purpose: MET is a potential therapeutic target in lung cancer and both MET tyrosine kinase inhibitors and monoclonal antibodies have entered clinical trials. MET signaling can be activated by various mechanisms, including gene amplification. In this study, we aimed to investigate MET amplification status in adeno- and squamous cell carcinomas of the lung. We propose clearly defined amplification scores and provide epidemiologic data on MET amplification in lung cancer. Experimental Design: We evaluated the prevalence of increased MET gene copy numbers in 693 treatment-naïve cancers by FISH, defined clear cutoff criteria, and correlated FISH results to MET IHC. Results: Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whereas 3% show a clear-cut high-level amplification (MET/centromer7 ratio ≥2.0 or average gene copy number per nucleus ≥6.0 or ≥10% of tumor cells containing ≥15 MET copies). The remaining cases can be subdivided into intermediate- (6%) and low-level gains (24%). Importantly, MET amplifications occur at equal frequencies in squamous and adenocarcinomas without or with EGFR or KRAS mutations. Conclusion: MET amplification is not a mutually exclusive genetic event in therapy-naïve non–small cell lung cancer. Our data suggest that it might be useful to determine MET amplification (i) before EGFR inhibitor treatment to identify possible primary resistance to anti-EGFR treatment, and (ii) to select cases that harbor KRAS mutations additionally to MET amplification and, thus, may not benefit from MET inhibition. Furthermore, our study provides comprehensive epidemiologic data for upcoming trials with various MET inhibitors. Clin Cancer Res; 21(4); 907–15. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0450

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 188

Metadata

Authors
Schildhaus, H.-U., Schultheis, A. M., Rüschoff, J., Binot, E., Merkelbach-Bruse, S., Fassunke, J., Schulte, W., Ko, Y.-D., Schlesinger, A., Bos, M., Gardizi, M., Engel-Riedel, W., Brockmann, M., Serke, M., Gerigk, U., Hekmat, K., Frank, K. F., Reiser, M., Schulz, H., Krüger, S., Stoelben, E., Zander, T., Wolf, J., & Buettner, R.
Venue
Clinical Cancer Research
Published
2015-02-15
Volume
21
Issue
4
Pages
907-915
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2110540279
Cited by
188
References
5
FWCI
9.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0450
The paper
Schildhaus, H.-U., Schultheis, A. M., Rüschoff, J., Binot, E., Merkelbach-Bruse, S., Fassunke, J., Schulte, W., Ko, Y.-D., Schlesinger, A., Bos, M., Gardizi, M., Engel-Riedel, W., Brockmann, M., Serke, M., Gerigk, U., Hekmat, K., Frank, K. F., Reiser, M., Schulz, H., . . . Buettner, R. (2015). MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0450

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.